COMPARE · Data as of August 24, 2026

BSX vs RDNT

Verdict: Side-by-side breakdown using the Bull Rankings model. BSX scored 78.1, RDNT scored 56.1 — BSX leads.
Compare another set
BSX
Boston Scientific Corporation
Medical Devices · Quality-Growth
78.1
$48.91 · $70.9B
fundamentals as of
Score gap
22.0
BSX leads
RDNT
RadNet, Inc.
Diagnostics & Research · Quality-Growth
56.1
$74.69 · $5.9B
fundamentals as of
  • Fastest growthRDNT+18.9%
  • Strongest balance sheetBSX0.50
  • Highest qualityBSX71 / 100
  • Largest discount to fair valueBSX-15%
THE BULL RANKINGS SCORECARD78.1/ 100 · BULL SCOREPEER MEDIANQUALITY71.2GROWTH88.4VALUE75.8
THE BULL RANKINGS SCORECARD56.1/ 100 · BULL SCOREPEER MEDIANQUALITY35.2GROWTH86.5VALUE58.1
BSXRDNTQuality71.235.2Growth88.486.5Value75.858.1
FCFBSX$3.6bRDNT$236m
RevBSX+13.5%RDNT+18.9%
D/EBSX0.50RDNT1.57
PEGBSX0.75RDNT0.96
BSX
stronger →← stronger
RDNT
71
Qualityreturns · margins · balance sheet
35
88
Growthrevenue & earnings expansion
86
76
Valuevaluation vs sector peers
58
BSX is stronger on 3 of 3 pillars.
BSX
RDNT
$3.6bB
FCF
$236mC
+13.5%B+
Rev
+18.9%B+
0.50B
D/E
1.57C
19.8xB+
P/E
0.75A-
PEG
0.96B+
P/S
2.6xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
BSX
RDNT
15% below
Price vs fair valuelower is cheaper
39% above
~0%/yr
Growth the price implies10-yr FCF · lower = less priced in
~24%/yr
+15%
1-yr DCF upside
-45%
+17%
5-yr DCF upside
-28%
+20%
10-yr DCF upside
+5%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
BSX
Why this score
  • Buying back stock
RDNT
Why this score
  • Diluting shareholders
BSXBoston Scientific Corporation
Medical Devices · $48.91 · beta 0.57
Why now
Medical Devices · market cap $70.9b. Down 55% from 52-week high of $109.50 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.75 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $62.69 (implying +28% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 15% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 99% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 55% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
RDNTRadNet, Inc.
Diagnostics & Research · $74.69 · beta 1.38
Why now
Diagnostics & Research · market cap $5.9b. 13% off the 52-week high of $85.84. Revenue growing +19%, comfortably above the S&P median. PEG 0.96 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $92.88 (implying +24% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -0.9%) — path to GAAP profitability is the core thesis risk. ROE -2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

Where BSX and RDNT diverge

On the headline score the gap is 22.0 points in favor of BSX. The widest single difference is Quality, where BSX leads by 36.0 points.

Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.